143 related articles for article (PubMed ID: 38015413)
21. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
Nóbrega G; Cavalcanti M; Leite V; Vilar L; Brandão SCS
Endocrine; 2022 Jun; 76(3):642-647. PubMed ID: 35237910
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
23. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma.
Lang BH; Wong KP; Wan KY; Lo CY
Ann Surg Oncol; 2012 Jan; 19(1):60-7. PubMed ID: 21681379
[TBL] [Abstract][Full Text] [Related]
24. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer.
Hughes DT; White ML; Miller BS; Gauger PG; Burney RE; Doherty GM
Surgery; 2010 Dec; 148(6):1100-6; discussion 1006-7. PubMed ID: 21134539
[TBL] [Abstract][Full Text] [Related]
25. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
26. Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma.
Lang BH; Wong KP; Wan KY
Ann Surg Oncol; 2013 Feb; 20(2):653-9. PubMed ID: 22956067
[TBL] [Abstract][Full Text] [Related]
27. SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.
Deng Y; Zhu G; Ouyang W; Pan L; Feng H; Wu J; Chen P; Wang J; Xian J
Endocr Pract; 2019 Sep; 25(9):887-898. PubMed ID: 31170371
[No Abstract] [Full Text] [Related]
28. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
[TBL] [Abstract][Full Text] [Related]
29. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
30. Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response.
Ahn J; Song E; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Endocrine; 2020 Mar; 67(3):623-629. PubMed ID: 31776976
[TBL] [Abstract][Full Text] [Related]
31. Significance of size of lymph node metastasis on postsurgical stimulated thyroglobulin levels after prophylactic unilateral central neck dissection in papillary thyroid carcinoma.
Lang BH; Tang AH; Wong KP; Shek TW; Wan KY; Lo CY
Ann Surg Oncol; 2012 Oct; 19(11):3472-8. PubMed ID: 22565664
[TBL] [Abstract][Full Text] [Related]
32. Is 131I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy?
Rosario PW; Mourão GF
Arch Endocrinol Metab; 2016 Feb; 60(1):5-8. PubMed ID: 26909477
[TBL] [Abstract][Full Text] [Related]
33. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
Mourão GF; Rosario PW; Calsolari MR
Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
[TBL] [Abstract][Full Text] [Related]
34. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
35. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).
Forleo R; Grani G; Alfò M; Zilioli V; Giubbini R; Zatelli MC; Gagliardi I; Piovesan A; Ragni A; Morelli S; Puxeddu E; Pagano L; Deandrea M; Ceresini G; Torlontano M; Puligheddu B; Antonelli A; Centanni M; Fugazzola L; Spiazzi G; Monti S; Rossetto R; Monzani F; Tallini G; Crescenzi A; Sparano C; Bruno R; Repaci A; Tumino D; Pezzullo L; Lombardi CP; Ferraro Petrillo U; Filetti S; Durante C; Castagna MG
Thyroid; 2021 Dec; 31(12):1814-1821. PubMed ID: 34541894
[No Abstract] [Full Text] [Related]
36. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
[TBL] [Abstract][Full Text] [Related]
37. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
38. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
Sun Y; Sun Q; Tian J; He X
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1413-e1423. PubMed ID: 37167097
[TBL] [Abstract][Full Text] [Related]
39. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.
Giovanella L; Ceriani L; Ghelfo A; Keller F
Clin Chem Lab Med; 2005; 43(8):843-7. PubMed ID: 16201895
[TBL] [Abstract][Full Text] [Related]
40. Intermediate-risk thyroid carcinoma: indicators of a poor prognosis.
Faro FN; Bezerra ÂMLB; Scalissi NM; Cury AN; Marone MM; Ferraz C; do Prado Padovani R
Arch Endocrinol Metab; 2021 May; 64(6):764-771. PubMed ID: 34033287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
